B+
Bull case
20%
Probability
Target price
$505.00
Analysis reference price unavailable
Analysis 2026-07-21 · RankAlpha Sentiment Codex
ISRG
Intuitive SurgicalBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$400.00
Analysis reference price unavailable
Analysis 2026-07-21 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$315.00
Analysis reference price unavailable
Analysis 2026-07-21 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-21
Recent news sentiment (30D)
-0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+73.8
Score
AI commentary
News tone is mixed-to-negative despite the primary-source earnings beat: the stock was reported down 12.69% on July 17, while analyst target revisions skewed lower. The packet has no usable social coverage and no analyst target count, so confidence is limited. This is a post-earnings monitoring setup rather than a clean momentum signal.
RankAlpha Sentiment Codex - 2026-07-21
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-31eventQ2 earnings beat, but near-term reaction remains mixedMedium impact
Q2 revenue rose 19% to $2.89 billion, non-GAAP EPS was $2.80, combined da Vinci and Ion procedures grew approximately 16%, and the installed bases continued expanding [#SEC-8K-2026-07-16]. The beat was followed by a sharp selloff as investors focused on slower U.S. procedure growth.
2026-08-07catalystPost-earnings de-rating and procedure-growth concernsHigh impact
Moderating U.S. da Vinci procedure growth, deferred elective procedures, GLP-1 pressure on bariatric volumes, and analyst target reductions could keep valuation pressure elevated. Analyst reaction included RBC lowering its target to $575 from $600 and Truist lowering its target to $510 from $580.
2026-12-31catalystDa Vinci 5 adoption and installed-base compoundingHigh impact
Da Vinci placements increased to 468, including 246 da Vinci 5 systems, while the da Vinci installed base reached 11,710 systems, supporting recurring instruments, accessories, leasing, and service revenue [#SEC-8K-2026-07-16].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology